Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?
Immunoglobulin (IG) replacement therapy has served as lifesaving treatment in primary
immunodeficiency diseases (PID) for more than six decades. Approximately 70% of patients …
immunodeficiency diseases (PID) for more than six decades. Approximately 70% of patients …
Intravenous immunoglobulin in critically ill adults: When and what is the evidence?
J Wang, ZK McQuilten, EM Wood, C Aubron - Journal of Critical Care, 2015 - Elsevier
Intravenous immunoglobulin (IVIg) use is growing dramatically internationally due to the
increasing numbers of acute and chronic conditions that may benefit from IVIg. Patients with …
increasing numbers of acute and chronic conditions that may benefit from IVIg. Patients with …
European consensus proposal for immunoglobulin therapies
WAC Sewell, J Kerr, ME Behr‐Gross, HH Peter… - 2014 - Wiley Online Library
The use of immunoglobulin (Ig) preparations (intravenous, IVIg, subcutaneous, SCIg) for
replacement and immunomodulation therapy worldwide has tripled in the past 20 years and …
replacement and immunomodulation therapy worldwide has tripled in the past 20 years and …
Study on the treatment of ITP mice with IVIG sourced from distinct sex-special plasma (DSP-IVIG)
W Zhang, X Yuan, Z Wang, J Xu, S Ye, P Jiang… - International Journal of …, 2023 - mdpi.com
Intravenous immunoglobulin (IVIG) is a first-line drug prepared from human plasma for the
treatment of autoimmune diseases (AIDs), especially immune thrombocytopenia (ITP) …
treatment of autoimmune diseases (AIDs), especially immune thrombocytopenia (ITP) …
Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long‐term outcome
M Nosadini, SS Mohammad, A Suppiej… - … Medicine & Child …, 2016 - Wiley Online Library
Aim Intravenous immunoglobulin (IVIG) is an expensive therapy used in immunodeficiency
and autoimmune disorders. Increasing demands and consequent shortages result in a need …
and autoimmune disorders. Increasing demands and consequent shortages result in a need …
Long‐term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study
L Querol, R Rojas‐Garcia, C Casasnovas… - Muscle & …, 2013 - Wiley Online Library
Introduction: The objective of this retrospective study was to describe the short‐and long‐
term patterns of IVIg use, safety, and response to treatment in patients with chronic …
term patterns of IVIg use, safety, and response to treatment in patients with chronic …
Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations
P Ripellino, T Fleetwood, R Cantello… - Autoimmune …, 2014 - Wiley Online Library
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease of
the peripheral nervous system, in which both cellular and humoral immune responses are …
the peripheral nervous system, in which both cellular and humoral immune responses are …
Comparison between IV immune globulin (IVIG) and anti‐D globulin for treatment of immune thrombocytopenia: a randomized open‐label study
To compare the effect of IV immune globulin (IVIG) and anti‐D globulin (anti‐D) for treatment
of immune thrombocytopenia (ITP) in children. A randomized, open‐label, single‐center …
of immune thrombocytopenia (ITP) in children. A randomized, open‐label, single‐center …
[HTML][HTML] Practise of immunoglobulin replacement therapy in primary and secondary immunodeficiencies: a single centre experience from Malaysia
NH Zahari, IJ Abd Hamid, SAT Din… - … Malaysian Journal of …, 2023 - ncbi.nlm.nih.gov
Background Intravenous immunoglobulin (IVIG) replacement therapy is increasingly in
demand. This study focused on the characteristics of IVIG usage and associated factors …
demand. This study focused on the characteristics of IVIG usage and associated factors …
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment
G Ellrichmann, R Gold, I Ayzenberg… - Therapeutic …, 2017 - journals.sagepub.com
Background: Administration of intravenous immunoglobulins (IVIgs) is established for long-
term treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) …
term treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) …